Table 6 Comparison of treatment between IBDU, CD and UC groups at last follow-up
From: Clinical features of inflammatory bowel disease unclassified: a case-control study
| Â | IBDU (37) | UC (74) | p-value | CD (74) | p-value |
|---|---|---|---|---|---|
surgery, n (%) | 15(40.5%) | 8(10.7%) | 0.000 | 27(36.5%) | 0.678 |
time from disease onset to surgery (months), median (IQR) | 56(16, 101) | 56.5(43.75, 115.25) | 0.540 | 21(12, 55.5) | 0.222 |
surgery complication, n (%) | 3(8.1%) anastomotic ulcer 1 anastomotic stenosis 2 | 0(0.0%) | Â | 6(8.1%) anastomotic ulcer 2 anastomotic fistula 1 anastomotic stenosis 3 | Â |
corticosteroid, n (%) | 36(97.2%) | 68(91.9%) | 0.897 | 58(78.4%) | 0.029 |
5-ASA, n (%) | 37(100.0%) | 74(100.0%) | -- | 67(90.5%) | 0.129 |
IM, n (%) | 23(62.1%) | 25(33.8%) | 0.004 | 51(68.9%) | 0.477 |
IFX, n (%) | 9(24.3%) | 13(17.6%) | 0.400 | 21(28.4%) | 0.650 |
time from disease onset to the use of IFX (months), median (IQR) | 80(63,116.5) | 35(15,81) | 0.035 | 69(17,113) | 0.428 |
courses of IFX, n median (IQR) | 12(7.5,17.5) | 6(4,10) | 0.032 | 12(7,15) | 0.964 |